Novo Nordisk moves to block compounded semaglutide sales, citing safety and patent risks
- Novo Nordisk sued Hims & Hers, seeking injunction and damages over allegedly patent‑infringing semaglutide risking patients' health.
- Novo says semaglutide patents run through 2032 and commercial compounding bypasses trials and manufacturing controls.
- Novo frames the dispute as an IP and safety issue, highlighting increased Wegovy manufacturing to prevent shortages.
Novo Nordisk moves to shore up Wegovy’s legal and safety perimeter
Novo Nordisk is pressing U.S. courts and regulators to block what it calls a mass‑compounding threat to its branded GLP‑1 obesity treatment, Wegovy. The company files suit seeking a permanent injunction and damages against telehealth provider Hims & Hers, alleging the firm markets cheaper, patent‑infringing copies of semaglutide that “deceive patients and put their health at risk.” Novo says semaglutide is protected by U.S. patents through 2032 and that broad commercial compounding bypasses the clinical trials and manufacturing controls that underpin approved products.
In pursuing judicial relief, Novo frames the dispute as both an intellectual property and public‑safety issue, arguing that unregulated, large‑scale compounding undermines regulatory rigor and scientific innovation. The company highlights its stepped‑up manufacturing to eliminate shortages for Wegovy and cites an industry estimate that up to 1.5 million Americans are using compounded GLP‑1 formulations made under a regulatory loophole. Novo’s legal action follows an escalation of enforcement by the U.S. Food and Drug Administration, which signals it will restrict access to ingredients used in the copycat pills and refer companies to the Department of Justice.
The case crystallises a broader industry effort by branded drugmakers to defend the clinical and regulatory framework for GLP‑1 medicines. Novo and competitors such as Eli Lilly are intensifying scrutiny of compounding practices they say risk product quality and patient safety while diluting incentives for costly drug development. Regulators, manufacturers and courts now face a test in balancing patient demand for lower‑cost options against the statutory protections and safety standards that govern approved therapies.
Hims & Hers pulls compounded semaglutide after FDA warning
Hims & Hers says it stops offering its compounded semaglutide pill after “constructive conversations with stakeholders,” immediately halting new prescriptions while regulators and the company consider next steps. The telehealth firm had planned a low‑cost oral alternative, promoting introductory pricing as low as $49, and is concurrently preparing a Super Bowl ad campaign that highlights health‑care inequities.
Access and policy tensions reshape the GLP‑1 market
Regulators’ enforcement and manufacturers’ legal moves are reshaping the market for obesity drugs, slowing proliferation of lower‑cost compounded alternatives and potentially preserving demand for approved injectables such as Wegovy. The dispute underscores ongoing policy questions about compounding rules, intellectual property boundaries and how to expand affordable access to fast‑growing GLP‑1 therapies without compromising safety.